Stemline prices IPO to raise funds for AML study as cash runs low
This article was originally published in Scrip
Executive Summary
With just a few million dollars in the bank, US cancer drug developer Stemline Therapeutics set a range of $11 to $13 per share on 19 July for its initial public offering of 3.5 million shares, but did not announce a date for the IPO, which would generate gross proceeds of $45.5 million at the high end of the stock price target.